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Outcomes from deep brain stimulation targeting subthalamic
nucleus and caudal zona incerta for Parkinson’s disease
Abteen Mostoﬁ 1,2,3, Julian M. Evans1, Lucy Partington-Smith1, Kenny Yu1,2, Cliff Chen1 and Monty A. Silverdale1,2
Both subthalamic nucleus (STN) and caudal zona incerta (cZI) have been implicated as the optimal locus for deep brain stimulation
(DBS) in Parkinson’s disease (PD). We present a retrospective clinico-anatomical analysis of outcomes from DBS targeting both STN
and cZI. Forty patients underwent bilateral DBS using an image-veriﬁed implantable guide tube/stylette technique. Contacts on the
same quadripolar lead were placed in both STN and cZI. After pulse generator programming, contacts yielding the best clinical
effect were selected for chronic stimulation. OFF-medication uniﬁed PD rating scale (UPDRS) part III scores pre-operatively and ON-
stimulation at 1–2 year follow up were compared. Active contacts at follow-up were anatomically localised from peri-operative
imaging. Overall, mean UPDRS part III score improvement was 55 ± 9% (95% conﬁdence interval), with improvement in subscores
for rigidity (59 ± 13%), bradykinesia (58 ± 13%), tremor (71 ± 24%) and axial features (36 ± 19%). Active contacts were distributed in
the following locations: (1) within posterior/dorsal STN (50%); (2) dorsal to STN (24%); (3) in cZI (21%); and (4) lateral to STN (5%).
When contacts were grouped by location, no signiﬁcant differences between groups were seen in baseline or post-operative
improvement in contralateral UPDRS part III subscores. We conclude that when both STN and cZI are targeted, active contacts are
distributed most commonly within and immediately dorsal to STN. In a subgroup of cases, cZI contacts were selected for chronic
stimulation in preference. Dual targeting of STN and cZI is feasible and may provide extra beneﬁt compared with conventional STN
DBS is some patients.
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INTRODUCTION
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is
effective in improving the motor complications of Parkinson’s
disease (PD) and is in widespread clinical use.1–5 The sensorimotor
subregion of STN is located in its dorsolateral aspect and is
commonly targeted in DBS for PD.6–8 The zona incerta is a region
of loosely arranged cell groups lying ventral to the thalamus and
dorsal to STN, in continuity with the thalamic reticular nucleus. Its
posterior part extends over the dorsum of STN to form a discrete
region—the caudal zona incerta (cZI), part of the region known as
the ‘posterior subthalamic area’—which lies immediately poster-
omedial to STN.9 Its connections are diffuse but include the basal
ganglia, motor areas of cerebral cortex and thalamus and the
cerebellar nuclei.10–12 Stimulation of cZI has been recently shown
to be more effective than best medical management in motor
improvement, with a particularly marked beneﬁt in tremor.13
Furthermore, a study comparing motor outcomes from DBS
targeting cZI versus dorsolateral STN in separate cohorts of
patients suggested that stimulation of cZI yielded signiﬁcantly
greater beneﬁt than that of dorsolateral STN.14
We have performed DBS targeting the subthalamic region
bilaterally as the routine surgical treatment of idiopathic PD in our
centre since 2011. Given the reported discrepancies in the optimal
stimulation locus, electrode trajectories were planned to place the
contacts of a quadripolar lead within both dorsolateral STN and
cZI. Here, we retrospectively report our clinical outcomes with this
approach. We perform a pragmatic observational analysis of the
anatomical location of the electrode contacts yielding the best
clinical effect and therefore selected for chronic stimulation (the
‘active’ contacts) post-operatively in order to shed light on which
subthalamic locus is the more effective target. We examine the
interaction between active contact location and underlying motor
characteristics of the study patients.
RESULTS
Efﬁcacy of DBS targeting STN and cZI
The primary outcome measure of total UPDRS part III score in the
entire study population post-operatively ON-stimulation/OFF-
medication was signiﬁcantly improved compared with the OFF-
medication pre-operative baseline (mean score from 55.2 to 24.7,
p < 0.001), with a mean relative improvement of 55 ± 9% (95%
conﬁdence interval). There were signiﬁcant improvements in
subscores for rigidity (59 ± 13%), bradykinesia (58 ± 13%), tremor
(71 ± 24%) and axial symptoms (36 ± 19%). Scores in UPDRS parts I
(evaluation of mentation, behaviour and mood), II (self-reporting
of activities of daily living) and IV (complications of therapy) also
saw highly signiﬁcant improvements following DBS surgery of
26 ± 14%, 24 ± 11% and 41 ± 16%, respectively (summarised in
Table 1). This clinical beneﬁt was accompanied by a 32 ± 8% mean
reduction in the levodopa equivalent daily dose (LEDD), with
LEDD increasing post-operatively in only a single patient.
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Localisation of active contacts
We were able to divide the 76 reconstructed active contact loci
into four groups based on the anatomical location of the contact
centroid: (1) dorsal to STN (18 electrodes; 24%); (2) within STN,
typically posteriorly and dorsally (38 electrodes; 50%); (3) poster-
omedial to STN, corresponding to the location of cZI or ‘posterior
subthalamic area’ (16 electrodes; 21%); and (4) immediately lateral
to STN (4 electrodes; 5%). The site and extent of these regions are
summarised in standard atlas representations in Fig. 1a–d with
speciﬁc examples from the source imaging illustrated in Fig. 1e–h.
As would be expected, active contacts in the region dorsal to STN
were more proximal on the quadripolar lead (median contact 3)
than those within STN (median contact 2) and those in cZI tended
to be even more distal (median contact 1; p < 0.001 for trend,
Kruskal–Wallis test), reﬂecting the planned incorporation of these
regions in a typical electrode placement (Fig. 2).
Mean X (lateral), Y (anterior) and Z (superior) coordinates of the
centroid of the active contact for the four anatomical locations,
relative to each individual’s mid-commissural point in the AC–PC
plane, in millimetres, were: dorsal to STN (13.2, −1.2, 0.2); within
STN (12.9, −2.9, −2.1); cZI (12.1, −4.5, −2.2); and lateral to STN
(14.0, −1.2, −1.7). Note that the X-coordinates for both right- and
left-sided electrodes are expressed as positive values for
comparability.
Relation of active contact location to clinical features
We assessed whether active contact location inﬂuenced the motor
improvement seen post-operatively. UPDRS part III rigidity,
bradykinesia and tremor subscores were determined for limbs
contralateral to each of the active contacts, as was the sum of the
three subscores (the ‘total’ score). Scores for active contacts lateral
to STN were excluded from statistical analysis due to the paucity
of data points. For the remaining three groups (dorsal to STN,
within STN and in cZI), signiﬁcant improvements attributable to
stimulation were seen in all motor subscores within all groups
(Table 2). No signiﬁcant inter-group differences in any of the
subscores were seen in the percentage individual improvement
seen ON-stimulation. There was also no difference in post-
operative LEDD reduction between the groups (p > 0.05,
Kruskal–Wallis test).
Given the lack of a clear relationship with motor improvement,
we asked whether the baseline pre-operative motor phenotype
inﬂuenced the location of the active contact selected during pulse
generator programming. Pre-operative OFF-medication contral-
ateral UPDRS part III rigidity, bradykinesia and tremor subscores
and their sum (the ‘total’ score) were compared across the three
groups. Again, no signiﬁcant inter-group differences were seen
(Kruskal–Wallis test; see Table 2).
Next, we determined if active contact location was associated
with any differences in stimulation parameters. This was based on
the theoretical consideration that if one of these locations is the
optimal stimulation target, then greater stimulation intensity may
be expected at the other more distant loci to achieve the
equivalent clinical effect seen. Stimulation frequency and pulse
width were invariant across all electrodes in our patients at 130 Hz
and 60 μs, respectively. Median stimulating current was lowest for
the active contacts within STN (2.34 mA) versus those dorsal to
STN (2.71 mA) and in cZI (2.97 mA), though the trend was not
statistically signiﬁcant (p= 0.087, Kruskal–Wallis test).
We noted that amongst the 16 leads with active contacts in cZI,
six did not have proximal contacts with centroids within STN. In
these six leads, proximal contacts were immediately adjacent to
the superomedial border of STN. For these leads, therefore, it
cannot be known if stimulation within STN, as deﬁned in this
study, would be superior to that of cZI. As a consequence, we
repeated the above analyses whilst excluding these six leads from
the cZI group. With this condition, we again found no signiﬁcant
inter-group differences in pre-operative motor scores, post-
operative motor improvement or stimulation parameters between
the groups of contacts (p > 0.05, Kruskal–Wallis test). We also
compared, within the cZI group, the pre-operative motor scores,
post-operative motor improvement and stimulation parameters
between the subgroup of leads with proximal contacts within STN
(n= 10) and that without (n= 6). No signiﬁcant differences were
seen between these two subgroups of cZI active contacts (p >
0.05, Wilcoxon rank-sum test).
Safety and accuracy of the technique
In the 40 patients included in this study, one patient (2.5%)
required a second procedure to re-implant the guide tubes that
were inaccurately placed due to intra-operative displacement of
the stereotactic frame. Two patients (5%) underwent skin erosion
at the pectoral IPG site requiring IPG removal. One patient (2.5%)
experienced pectoral skin erosion managed surgically and with
prolonged intravenous antibiotics without IPG removal. On the
intra-operative imaging studies, no intracranial haematomas,
pneumocephalus or signiﬁcant brain shift were demonstrated.
Mean scalar error in electrode placement was 1.3 ± 0.1 mm
(95% conﬁdence interval) with no signiﬁcant difference between
left- and right-sided electrodes (p= 0.483, two-sample t-test). Fifty
seven percent of electrodes were placed within one electrode
diameter (1.27 mm) and 99% within two diameters in the axial
plane of the planned cZI target locus.
DISCUSSION
In this ‘real-world’ retrospective observational study, we report our
outcomes from bilateral subthalamic DBS for PD in which we have
intentionally targeted both STN and cZI on a single trajectory. This
targeting strategy was motivated by the fact that while there is a
large body of high-quality evidence supporting STN as a target for
DBS for PD,1–5 others have achieved good results with cZI
stimulation13–15 and one group has reported superior efﬁcacy with
cZI compared with STN.14 On a pragmatic level, the mean
improvement in the overall OFF-medication UPDRS part III score of
55% from baseline in the whole study population compares well
against published data from bilateral STN DBS.4,5,16,17 This shows
that our targeting strategy produces outcomes no less favourable
than when STN is targeted conventionally. This improvement is
Table 1. UPDRS outcome data and levodopa equivalent daily dose
(LEDD) for all 40 patients
Baseline
score, mean
Post-DBS
score, mean
Mean percent
improvement (95%
C.I.)
UPDRS-III 55.2 24.7 55% (46–65)
Rigidity 10.8 4.4 59% (46–72)
Bradykinesia 21.0 8.7 58% (45–72)
Tremor 9.7 2.8 71% (47–95)
Axial 10.2 6.5 36% (17–55)
UPDRS-I 13.4 10.0 26% (11–40)
UPDRS-II 19.8 15.1 24% (12–35)
UPDRS-IV 8.8 5.2 41% (25–57)
LEDD/mg 1233 825 32% (24–40)
Mean baseline pre-operative OFF-medication and post-operative ON-
stimulation/OFF-medication UPDRS part III total score and subscores for
rigidity, bradykinesia, tremor and axial features are shown. Mean baseline
pre-operative and post-operative scores for UPDRS parts I, II and IV and
LEDD are also presented. All comparisons between baseline and post-DBS
scores were highly signiﬁcant (p < 0.001; paired t-test)
A. Mostoﬁ et al.
2
npj Parkinson’s Disease (2019)    17 Published in partnership with the Parkinson’s Foundation
1
2
3
4
5
6
7
8
9
0
()
:,;
Fig. 1 Anatomical locations of the active contacts were divided into four groups, the site and extent of each indicated by coloured shading in
representative labelled example sections (a–c axial, d coronal) from the stereotactic atlas of Schaltenbrand and Wahren21: within STN (blue);
dorsal to STN (purple); posteromedial to STN, in cZI (red); and lateral to STN (green). e–h Typical examples of images used to localise
electrodes is presented for each active contact location. The intra-operative study is fused with the planning MRI scan in the plane of the
active contact centroid. The stylette artefacts (coloured arrows; colours as in a–d) from the intra-operative imaging (CT study in e, f and h; MRI
study in g) are thus visible on the anatomical planning scans and allow contact localisation. e–g show axial and h coronal slices. STN and red
nucleus (RN) are labelled
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reﬂected in all four cardinal motor domains in keeping with
previous accounts of STN DBS. Signiﬁcant improvements are also
seen in motor ﬂuctuations as assessed by the part IV (complica-
tions of therapy) score, and in non-motor assessments reﬂected in
the part I (mentation, behaviour and mood) and part II (activities
of daily living) scores of the UPDRS, replication of which in the
literature has been variable.2,4,5,16,17
We are only the second group to report a large series of DBS
operations using an image-veriﬁed implantable guide tube/
stylette method described previously.18–20 The technique’s
beneﬁts include the ability to localize stylette location readily on
intra-operative magnetic resonance imaging (MRI) or computed
tomography (CT) without electrode artefact, as exploited in this
study, and the potential to revise hardware without the need to
repeat the stereotactic process. We have demonstrated that this
method can be performed safely, accurately and effectively in a
second centre and is therefore scalable.
Our major objective in this study was to review the locations of
active contacts selected during pulse generator programming for
chronic stimulation in order to shed light on which out of STN and
cZI is the more frequently stimulated and therefore more effective
target. In this regard, we performed a pragmatic retrospective
clinico-anatomical analysis utilising routinely collected clinical
data. At the time of follow up when contact selection and
programming is expected to have been optimised, we determined
the location of the active electrode contacts selected for chronic
stimulation to identify which loci were being stimulated. We
demonstrate that with our targeting strategy, the most frequent
locus for active contacts is within the dorsal and posterior part of
STN, as seen in half of our electrode implantations. This area is in
keeping with the sensorimotor part of STN previously described
and targeted.7,8 This was followed by the region immediately
dorsal to STN and ventral to the thalamus in approximately one
quarter of leads. In this area resides the rostral zona incerta
located in between ﬁelds H2 and H1 of Forel in which pallido- and
cerebello-thalamic projection ﬁbres are found.10,21 Some previous
studies examining the relationship between active contact
location and therapeutic effect have implicated this region as
the most effective locus, and activation of pallidofugal ﬁbres has
been suggested as a putative mechanism.22–26
These two sites—STN and its dorsal border area—together
account for almost three quarters of the implanted leads.
Therefore, targeting the STN and placing contacts within the
nucleus and over its dorsal border—as would normally be
performed in conventional STN DBS—appears to be more
important than targeting cZI in the majority of cases. This
contradicts a previous ﬁnding demonstrating the superiority of
cZI stimulation over that of STN.14 However, in approximately one
in ﬁve of our implanted leads, the active contact was located in
cZI. In the majority of cases where cZI was selected for chronic
stimulation, the cZI contact was selected in preference to proximal
contacts in STN. This implies that stimulation of cZI conferred
more beneﬁt than that of the other regions during pulse
generator programming in this subgroup of implantations. We
therefore propose that targeting cZI in addition to STN, as we
report in this study, may provide a more effective stimulation
locus for a minority of implanted leads that may beneﬁt a sizeable
fraction of patients undergoing DBS therapy for PD.
We sought to determine if the location of active contacts was
related to clinical features seen in the study population. We
demonstrate no signiﬁcant association between active contact
location and contralateral motor improvement, neither in the total
change in contralateral UPDRS part III score nor in the subscores
for rigidity, akinesia and tremor. In other words, as long as the
most effective contact is selected during programming for chronic
stimulation, its speciﬁc location—be it dorsal to STN, within STN or
in cZI—does not inﬂuence the derived motor beneﬁt (although a
recent study suggests non-motor improvement may be
affected27). Furthermore, the pre-operative contralateral motor
scores were not different between patients with active contacts in
the three different areas, suggesting that pre-operative motor
phenotype is not a signiﬁcant determinant of the most effective
stimulation locus. We are therefore unable to shed light on why a
particular contact is chosen over the others in individual patients
when across the population active contacts are located in these
different regions. The choice of contact used may well be
determined more by the side effect proﬁle of stimulation rather
than by the motor features of PD that are explored in this study,
however we were unable to examine this further from the clinical
records available. The therapeutic effect of cZI stimulation may lie
in the extent of activation of ﬁbre bundles within the activated
ﬁeld, namely the thalamic and lenticular fasciculi.11 These bundles
cannot be resolved directly with conventional clinical imaging,
which may account for some variability in contact placement
Fig. 2 Typical planned electrode trajectories for bilateral subthalamic DBS. a Axial T2-weighted MRI with STNs marked in blue outline. Red
asterisks represent the cZI target loci posteromedial to STN. Trajectories illustrated relative to STN (rendered blue volume) viewed posteriorly
b and superiorly c on digital three-dimensional reconstructions from the planning software. The four contacts on each quadripolar Medtronic
3389 lead are visible. The distal contact 0 lies at the cZI target locus, more proximal contacts 1 and 2 within STN and the most proximal
contact 3 just dorsal to STN
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relative to these structures and impact upon the relative efﬁcacy
of cZI versus STN stimulation in individual cases.
Localisation of the active contacts using the method described
above is subject to potential limitations and sources of error,
namely that are introduced by MR distortion and CT-MRI image
co-registration. Co-registration accuracy for plain CT and MRI using
the same software as this study has recently been reported as well
within the sub-millimetre range.28 Our own preliminary data
suggest that our method of using a CT angiogram may provide
even further accuracy by allowing vasculature close to the region
of interest to provide feature detail for improved co-registration.
We infer that the implanted electrode will be in exactly the same
location as the stylette. This relies on the demonstrated
effectiveness of our precautions for preventing intra-operative
brain shift. We have deﬁned an active contact’s location based on
its centroid. In reality, it is a cylinder of length 1.5 mm and
diameter 1.27 mm and the volume of tissue it activates will be
even larger than this. Therefore, the volume of tissue activated by
a contact will be greater than the point locus representing its
location and may include structures neighbouring that in which
the locus resides. Electrical stimulation parameters were not
signiﬁcantly different between the three main groups, rendering it
unlikely that the distribution of active contact locations can be
accounted for fully by spread of current to a true single ‘best’ locus
nearby. However, it must be acknowledged that the lack of
statistical difference between groups could be attributed to the
sample size in this study. Further investigation of DBS targeting
different subthalamic structures in larger numbers of patients may
yield further insights into the key determinants of target selection.
In conclusion, in this pragmatic observational study of DBS for
PD, we demonstrate that our method of dual targeting of the STN
and cZI is safe, accurate and effective, with outcomes that
compare favourably to existing published data on STN DBS. The
negative contact yielding the best clinical effect and chosen for
chronic stimulation is located within the STN or dorsal to it in
around three out of four cases. The cZI contact is chosen in
preference to contacts within and dorsal to the STN in
approximately one ﬁfth of implantations. We therefore propose
that targeting cZI in addition to STN on a single trajectory is
practicable and provides an extra therapeutic option that may
yield greater beneﬁt than conventional STN DBS for some
patients.
METHODS
Patients
We present a detailed clinical and anatomical targeting analysis of our ﬁrst
40 patients implanted with DBS electrodes for idiopathic PD as part of their
routine clinical care. Patients were selected based on well-established
criteria for DBS by a mutli-disciplinary team.29 Baseline characteristics of
participants are summarised in Table 3. All patients gave written informed
consent for the use of anonymised routine clinical data for audit and
research. This study was approved by the Manchester Centre for Clinical
Neurosciences, Salford Royal NHS Foundation Trust, Greater Manchester,
United Kingdom.
Pre-operative planning and target deﬁnition
A planning MRI study of the brain acquiring high-resolution 1.5T T2-
weighted (repetition time 4525ms, echo time 140ms) axial, coronal and
sagittal, and volumetric gadolinium-enhanced T1-weighted images (repe-
tition time 20ms, echo time 4.6 ms) was obtained under general
anaesthesia. Target loci in cZI were identiﬁed immediately medial to the
medial border of the posterior third of STN at the level of the maximal
diameter of the red nucleus in the axial plane parallel to the anterior
commissure—posterior commissure (AC–PC) line. Trajectories with frontal
and lateral entry points were planned for quadripolar leads (Model 3389,
Medtronic, USA) using dedicated software (neuroinspire™, Renishaw, UK).
Trajectories were drawn typically to position the distalmost contact 0
Table 2. Median and interquartile range (IQR) of baseline pre-
operative OFF-medication and post-operative ON-stimulation/OFF-
medication UPDRS part III subscores for contralateral (C/L) rigidity,
bradykinesia and tremor, and their sum total (total UPDRS-III), for the
three groups of active contacts located dorsal to STN, within STN
and in cZI
Baseline
score,
median (IQR)
Post-DBS
score,
median (IQR)
Individual
percent
improvement,
median (IQR)
p-value
C/L rigidity
Dorsal to STN 4 (1–6) 1 (0–3) 40% (25–100) 0.001
Within STN 5 (3–6) 2 (1–3) 60% (33–83) <0.001
In cZI 5 (3–6) 2 (0–2) 75% (38–100) <0.001
Inter-group
p-value
0.308 0.529
C/L bradykinesia
Dorsal to STN 9 (4–14) 3 (1–3) 68% (21–79) 0.001
Within STN 11 (7–15) 3 (2–6) 70% (33–82) <0.001
In cZI 9 (6–15) 3 (2–5) 62% (34–80) 0.001
Inter-group
p-value
0.450 0.886
C/L tremor
Dorsal to STN 5 (1–9) 1 (0–2) 75% (8–93) 0.001
Within STN 3 (0–4) 0 (0–1) 100% (50–100) <0.001
In cZI 0 (0–7) 0 (0–2) 71% (50–91) 0.031
Inter-group
p-value
0.066 0.287
C/L total UPDRS-III
Dorsal to STN
(n= 18)
17 (12–24) 5 (3–7) 65% (50–74) <0.001
Within STN
(n= 38)
19 (13–24) 6 (4–10) 69% (37–78) <0.001
In cZI (n= 16) 18 (11–22) 6 (3–9) 72% (51–75) <0.001
Inter-group
p-value
0.810 0.916
Also shown are medians and IQRs of the individual percentage
improvement in the scores seen post-operatively. Intra-group pre- and
post-operative absolute scores are compared and p-values are shown in
the rightmost column (two-tailed Wilcoxon signed-rank test). Pre-operative
baseline scores and post-operative individual percentage improvement in
scores are compared between groups (inter-group p-values shown;
Kruskal–Wallis test) with no signiﬁcant inter-group differences
Table 3. Baseline characteristics of the 40 patients in the study at the
time of surgery
Age/years (mean ± SD) 59 ± 9
Sex
Male 28 (70%)
Female 12 (30%)
Duration of disease/years (mean ± SD) 9 ± 3
Baseline LEDD/mg (mean ± SD) 1233 ± 608mg
Hoehn and Yahr stage (median, range) 2 (1–5)
Indication for DBS
Motor ﬂuctuations and dyskinesia 33 (83%)
Disabling tremor 7 (17%)
LEDD levodopa equivalent daily dose,30 SD standard deviation
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within the target cZI locus and the more proximal contacts 1 and 2 within
the posterior third of STN (Fig. 2). Typical trajectory angles were 35–50°
anterior in the sagittal plane and 15–30° lateral in the coronal plane in
Cartesian space deﬁned by the AC–PC plane, and skull entry points were
anterior to the coronal suture.
The ﬁrst ten patients underwent the planning MRI study on the day of
surgery in a Leksell stereotactic frame (Co-ordinate Frame G, Elekta,
Sweden). For subsequent patients it was performed without the frame
days prior to surgery and was co-registered with a stereotactic CT
angiogram (0.625mm slice thickness) in the Leksell frame obtained on the
day of surgery, using the Circle of Willis as a region of interest.
Surgical technique and peri-operative imaging
Bilateral DBS leads were implanted under general anaesthesia based on
the guide tube/stylette method previously described by others20
(neuroguide™ system, Renishaw, UK). A plastic guide tube cut 12mm
shorter than the planned trajectory length was inserted stereotactically
towards the target over a rigid probe and bonded to the skull with acrylic
bone cement. A plastic stylette was inserted through each guide tube
along the planned trajectory and its location veriﬁed with intra-operative
stereotactic imaging in the frame (volumetric gadolinium-enhanced T1-
weighted MRI scan for the ﬁrst ten patients, and volumetric CT scan for the
remainder). If targeting accuracy on the intra-operative imaging study was
deemed satisfactory, the stylettes were removed and DBS leads were
passed down the guide tubes to exactly the same depth and connected
via extension leads to a pulse generator (Activa PC or Kinetra, Medtronic,
USA) subcutaneously implanted in the chest or abdominal wall.
Stimulator programming
Around four weeks after surgery, participants were admitted for stimulator
programming. Programming was performed using a standardised proto-
col. Patients were programmed in the OFF-medication state (after 12 h
withdrawal of PD medication). The left-sided lead was tested initially using
monopolar review of each contact separately from distal to proximal
(contacts 0, 1, 2 and 3). Initial pulse width was 60 µs and frequency was
130 Hz. The stimulator amplitude was then gradually increased from 0 to
6 V checking for any beneﬁcial effects and any side effects. All contacts
were tested systematically, before deciding on the optimal contact. The
optimal contact was chosen as the one that provided good symptom
control and a large therapeutic window (no side effects up to 6 V, or side
effects occurring at least 1.5 V higher than beneﬁcial effects). If no optimal
contact could be found after monopolar testing of all contacts, then
bipolar and tripolar stimulation was attempted. Subsequently the right-
sided lead was systematically tested in a similar systematic fashion.
Determination of electrode active contact locations
For 38 patients (76 leads) the location of the implanted stylettes was able
to be veriﬁed accurately. In the remaining two patients the intra-operative
imaging allowed broad veriﬁcation of implantation accuracy but was not
of sufﬁcient resolution to allow detailed reconstruction of stylette
placement. In each patient, the intra-operative imaging study was co-
registered with the pre-operative planning MRI study. The trajectories of
the stylettes—and hence of the leads—were deﬁned in Cartesian
coordinates relative to the AC–PC plane and mid-commissural point as
determined on each patient’s own planning MRI study (X, right lateral; Y,
anterior; Z, superior). The active (negative) contact and stimulation
parameters at the time of follow-up clinical assessment between one
and two years post-operatively were obtained from the clinical notes. The
anatomical location of each active contact centroid was retrospectively
determined and visualised on a fused image of the planning MRI and intra-
operative imaging study. This location was transposed onto the
representative Schaltenbrand and Wahren atlas section21 for illustrative
purposes using the axes of STN as a guide for the transposition as
described by others previously.14 In order to evaluate the implantation
technique used, any discrepancies between planned and actual trajec-
tories were quantiﬁed in terms of Euclidean vector error in X and Y
dimensions of the centre of the electrode shaft from the planned cZI target
locus in the same axial (Z) plane. The magnitude of this vector error is the
reported scalar error. Conﬁdence limits for targeting error were derived
using the t-distribution.
Outcome measures
Movement disorder society uniﬁed PD rating scale (UPDRS) scores were
assessed before surgery (baseline) and between one and two years post-
operatively. All assessments were performed by a single investigator (L.P.-
S.) who was blinded to the location of the active contact in post-operative
patients. Median interval between surgery and assessment at follow-up
was 16.5 months (range 11–27 months). The primary outcome measure
was the total UPDRS part III (clinician-scored motor evaluation) score ON-
stimulation/OFF-medication at follow-up versus the pre-operative OFF-
medication score. Secondary outcome measures included post-operative
OFF-medication change in UPDRS part III subscores for bradykinesia (items
3.4–3.8), rigidity (3.3), tremor (3.15–3.18) and axial symptoms (3.9–3.14),
and post-operative change in UPDRS parts I (evaluation of mentation,
behaviour and mood), II (self-evaluation of activities of daily living) and IV
(complications of therapy). Mean baseline and post-operative scores were
compared using a paired two-tailed t-test (n= 40) and 95% conﬁdence
intervals for the mean change derived from the t-distribution.
We investigated whether differences in active contact location impacted
upon the motor improvement seen post-operatively. The electrodes were
grouped based on the anatomical location of the centroid of each active
contact. Within each group, baseline OFF-medication and post-operative
ON-stimulation/OFF-medication UPDRS part III subscores for bradykinesia,
rigidity and tremor pertaining to the contralateral limbs were compared, as
was the sum of three subscores (the ‘total’ score; Wilcoxon signed-rank
test). For each subscore, inter-group differences in the individual post-
operative percentage changes from baseline and the pre-operative
baseline scores were examined (Kruskal–Wallis test). The active contacts
lateral to STN were excluded from statistical analysis due to paucity of
observations.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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